|
Partnering Philosophy & Corporate Partners
CEL-SCI’s partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of:
- The patients who are/will be treated,
- The scientific, clinical, and commercial development of the medicine and
- CEL-SCI's shareholders.
CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.
Multikine®:
CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine® on its own for head and neck cancer in both the United States and Europe once it is licensed. Since its primary target market, head & neck cancer surgeons, is small, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine®, once it is licensed. Larger sales forces may be needed to sell Multikine® for other indications, such as breast cancer, skin cancer and enhancement of radiation or chemotherapy.
Current Corporate Partners:
- Byron Biopharma
| |
a. |
Agreement Signed March 2009 |
|
| |
b. |
Territory – Republic of South Africa |
|
| |
c. |
Revenue Share |
|
- Teva Pharmaceuticals Industries Ltd.
- Orient Europharma Co. Ltd.
| |
a. |
Agreement Signed November 2000 |
|
| |
b. |
Territory - Taiwan, Singapore, Hong Kong, Malaysia, South Korea, the Philippines, Australia and New Zealand |
|
| |
c. |
Revenue Share |
|
| |
d. |
Website - http://www.oep.com.tw/ |
|
Other Partnering Possibilities:
Based on the Company's L.E.A.P.S. technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology. The two leading candidates derived from this technology are the H1N1 treatment for hospitalized patients and the Rheumatoid Arthritis treatment vaccine.
|
